Shanghai HeartCare’s Novel Intracranial Drug-Eluting Stent Application Accepted by China’s NMPA

Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has issued an announcement.

Shanghai HeartCare Medical Technology Corporation Limited has announced that China’s National Medical Products Administration has accepted the registration application for its self-expanding intracranial drug-eluting stent, designed to treat intracranial atherosclerotic stenosis by supporting and reopening narrowed or blocked vessels while reducing the risk of in-stent restenosis. The company highlights that, based on publicly available information, there are currently no comparable products approved for marketing worldwide, underscoring the stent’s potential to reinforce HeartCare’s technological leadership in neurovascular intervention, even as it cautions investors that successful commercialization is not guaranteed and regulatory outcomes remain uncertain.

The most recent analyst rating on (HK:6609) stock is a Buy with a HK$71.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H

Shanghai HeartCare Medical Technology Corporation Limited is a China-based medical technology company focused on developing innovative neurovascular medical devices. The Group specializes in interventional products for the treatment of cerebrovascular diseases, targeting conditions such as intracranial atherosclerotic stenosis and positioning itself at the leading edge of neuro-interventional technology in the domestic and potentially global markets.

Average Trading Volume: 66,299

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.18B

For a thorough assessment of 6609 stock, go to TipRanks’ Stock Analysis page.